Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1 1

Status

Completed 123Active not recruiting 20Terminated 16Unknown 14Recruiting 4Withdrawn 3Not yet recruiting 1

Sponsor Class

OTHER 185INDUSTRY 117OTHER_GOV 9NIH 4NETWORK 2

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Papillary renal cell carcinoma, sporadic 1Lung Neoplasms 1Hereditary leiomyomatosis and renal cell cancer 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 116Magnetic Resonance Spectroscopy 77Biopsy 71Cyclophosphamide 24pembrolizumab 22Cisplatin 21fludarabine 18Platinum 171,2-diaminocyclohexaneplatinum II citrate 17Taxes 16Paclitaxel 16Carboplatin 16Nivolumab 15Immunoglobulin G 15Disulfides 15X-Rays 13Radiation 13venetoclax 12Doxorubicin 12Radiotherapy 11Gemcitabine 11durvalumab 10Prednisone 9cabozantinib 8aldesleukin 8olaparib 7decitabine and cedazuridine drug combination 7atezolizumab 7Cytarabine 7lutetium Lu 177 dotatate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × NIH × Bevacizumab × Clear all
NCT07198074 2026-05-27

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
255 enrolled
Gynecologic

Endometrial Neoplasms

NCT04181060 2026-05-18

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

National Cancer Institute (NCI)

Phase 3 Recruiting
300 enrolled
Thoracic

Lung Neoplasms

NCT04981509 2026-05-13

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
65 enrolled
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Papillary renal cell carcinoma, sporadic, Carcinoma, Renal Cell

NCT06696768 2026-05-13

Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Recruiting
24 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡